Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and G...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurovirology 2020-10, Vol.26 (5), p.797-799
Main Authors: Abrams, Rory M.C., Kim, Brian D., Markantone, Desiree M., Reilly, Kaitlin, Paniz-Mondolfi, Alberto E., Gitman, Melissa R., Choo, S. Yoon, Tse, Winona, Robinson-Papp, Jessica
Format: Article
Language:English
Subjects:
Acute Disease
Aged
Anticoagulants - therapeutic use
Betacoronavirus - pathogenicity
Biomedical and Life Sciences
Biomedicine
Case Report
Coronavirus Infections - complications
Coronavirus Infections - pathology
Coronavirus Infections - therapy
Coronavirus Infections - virology
COVID-19
Disease Progression
Enoxaparin - therapeutic use
Female
Guillain-Barre Syndrome - complications
Guillain-Barre Syndrome - pathology
Guillain-Barre Syndrome - therapy
Guillain-Barre Syndrome - virology
Humans
Hyponatremia - complications
Hyponatremia - pathology
Hyponatremia - therapy
Hyponatremia - virology
Immunology
Infectious Diseases
Neurology
Neurosciences
New York City
Pandemics
Plasmapheresis
Pneumonia, Viral - complications
Pneumonia, Viral - pathology
Pneumonia, Viral - therapy
Pneumonia, Viral - virology
SARS-CoV-2
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
ISSN:1355-0284
1538-2443
DOI:10.1007/s13365-020-00884-7